PrimeC is NeuroSense's investigational combination oral therapy for amyotrophic lateral sclerosis, built to target multiple pathological pathways such as neuroinflammation and motor-neuron degeneration. Clinical development has included Phase 2/2b work and progression toward pivotal Phase 3 plans after FDA clearance. The product remains unapproved.
JAMA Neurology published Phase 2b PARADIGM results for PrimeC in ALS, showing slower functional decline, fewer ALS-related complications and longer survival. NeuroSense is preparing a Phase 3 trial and received Brazilian patent protection through October 2042.
PrimeC, an oral combination therapy, showed safety and signals of clinical benefit in a phase 2b trial, while PLL001, a gut-targeting therapy, demonstrated positive safety and tolerability in a phase I/II study for amyotrophic lateral sclerosis.
